Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns

Letter to the Editor
  • 8 Downloads

Notes

Compliance with Ethical Standards

Conflict of interest

The author declares there is no conflict of interest, and there are no financial disclosures to be made.

References

  1. 1.
    Elsersy MAM. Efficacy of combined cabergoline and metformin compared to metformin alone on cycle regularity in patients with polycystic ovarian disease with hyperprolactinemia: a randomized clinical trial. J Obstet Gynecol India. 2017;67(5):363–9.CrossRefGoogle Scholar
  2. 2.
    Krysiak R, Kowalcze K, Szkrobka W. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med. 2016;30:94–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013;62:1522–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Corbett S, Shmorgun D, Claman P, et al. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2014;36(11):1024–33.CrossRefPubMedGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyWomen Health Hospital, Assiut UniversityAssiutEgypt

Personalised recommendations